Andrei Surguchov, Ph.D.
VA Medical Center,
**** **** ******* *********, ****** City, MO 64128
**** ******* *********, ****** ********** Medical Center, 66160
A challenging position of Medical Writer, which requires qualities of a strong technical leader and manager with excellent strategic and customer-focused leadership. The position is based on my broad experience in biomedical field and expertise in medical writing of scientific and regulatory clinical documents and overseeing of junior and administrative staff. Ph.D. in biochemistry and Diploma of Clinical Research Associate/Administrator (CRA) from Kriger Research Institute (NYC).
SUMMARY OF QUALIFICATION:
Extensive medical knowledge, expertise in multiple therapeutic areas. Familiarity with drug development and medical, legal, and regulatory issues. Knowledge of protocols, protocol amendments, Investigator Brochures (IB)s, study reports, lnvestigational New Drug (IND) Application, IND annual reports, other regulatory submissions.
Expertise in writing, editing and reviewing the content of strategic medical regulatory documents enabling global regulatory submissions and product approvals. As a member of the R@D Committee, I participate in writing, managing and reviewing of clinical submission documents, including integrated summaries, Module 2 summaries, investigator brochures (IBs), CSRs, CTD documents and clinical overviews.
Experience in writing and reviewing clinical study documents, including protocols, study reports, and informed consent forms.
Expertise on the research of mechanisms of human diseases based on knowledge of biochemistry, molecular biology and pharmacology.
Ability to clearly articulate scientific and clinical data in written and verbal communication
Reliable time management skills and ability to manage expectations and time pressures
associated with responding to client needs. As a head of the laboratory supervised a group of
three researchers using managerial skills.
As a researcher and a head of the lab I performs literature searches and prepare summaries of
literature. More than 20 review articles are published in high ranking biomedical journals (see
list of publications below).
Experience with advanced writing features in MS Word.
As a head of the laboratory and a member of the R@D Committee I acquired project and people management experience. Furthermore, as a faculty member in the Department of Neurology, KUMC I acquired broad expertise in human diseases and their treatment.
Experience in preparation of scientific articles in leading biomedical journals (see List of publications below). Expertise and comfort in writing, developing and editing medically-relevant scientific content in the form of oral presentation, abstracts, posters, slides and grant proposals.
Excellent team-working and oral and written communication skills as evidenced by:
oPreparing scientific data for publication: published ~75 review and research papers.
oPreparing and giving presentations in either oral or poster formats:
30 oral and poster presentations at a variety of scientific meetings.
Writing grant proposals for federal institutions and private foundations. More than 10 of them were funded.
Troubleshooting and optimization of experimental procedures.
Analysis of complex scientific results both for laboratory experiments and published data.
Ability to clearly articulate scientific and clinical data in written and verbal
communication. Experience with advanced writing features in MS Word and other
Microsoft Office software.
Editing and reviewing manuscripts for a peer-reviewed journals. Member of editorial boards in ~12 journals, reviewer in many biomedical journals.
Working in a goal-oriented collaborative environment.
oInstructed and supervised junior team members.
oEstablished successful relationships with key opinion leaders, scientists and physicians.
Special Emphasis Panel/Scientific Review Group CSR/NIH, Challenge Grants (Panel 3).
Reviewer of applications in NINDS/NIH, in response to RFA-NS-17-016 (Apr 2017).
Reviewer in the Alzheimer's Association International Research Grant Program.
Reviewer in Israel Science Foundation (ISF, 2017). Parkinson’s UK; Glaucoma Foundation; The University of Kansas Alzheimer’s Disease Center; Midwest Biomedical Research Foundation (MBRF). Established successful relationships with key opinion leaders, scientists and physicians.
Member of R@D Committee, VA Medical Center, Kansas City.
Committee Member-Reviewer, 7th WSEAS International Conference on Biochemistry and
Medical Chemistry (BIOMEDCH '13), Paris, France, October 2013.
The 2014 International Conference on Biology and Biomedicine (BIO2014), Prague, Czech
Republic, April 2-4, 2014, International Liaisons.
The 2015 International Conference on Biology and Biomedicine (BIO 2015), Barcelona,
Spain, April 7-9, 2015 International Liaisons.
Program Committee: The 2015 International Conference on Biology and Biomedical
Engineering, BBE, Vienna, Austria, March 15-17, 2015).
Committee Member-Reviewer, 6th International Conference on Bioscience and
Bioinformatics (ICBB '15), Dubai, United Arab Emirates, February 22-24, 2015.
Committee Member-Reviewer, 5th International Conference on Biotechnology, Food and Animal
Science, Barcelona - ABIFA '16
Honorable Organizing Committee Member, 2nd World Congress on Biopolymer, Manchester, UK,
Organizing Committee Member at Biopolymers and Bioplastics-2017, 5th International Conference
and Exhibition on Biopolymers and Bioplastics, October 19-21, 2017, San Francisco, USA.
Editor in Biomedical Research International, Associate Editor in Frontiers in Molecular Neuroscience,
Frontiers of Cellular Biochemistry, Cell and Developmental Biology, Molecular Biosciences,
Certificate of Outstanding reviewer in Tissue and Cell, Archives of Biochemistry and Biophysics, 2017,
2018. Certificate of Recognized reviewer in Tissue and Cell, Archives of Biochemistry and
Biophysics, Experimental Eye Research, Molecular and Cellular Neuroscience, Neuroscience
Letters, FASEB and other journals.
KEY RESEARCH CONTRIBUTIONS:
Research biologist and Medical writer 2001- 2016 - VA Medical Center, Kansas City, MO
2009- current – Professor, Kansas University Medical Center (joint appointment)
Wrote and edited 20 manuscript for high ranking biomedical journals, all of them were published.
Wrote and submitted 18 grant proposals, 5 of which were funded.
Wrote and submitted 16 Abstracts and texts for oral presentations for national and International
meetings all of which were presented.
Discovered a role of gamma-synuclein as the major contributor to the molecular mechanism of neurodegenerative diseases and cancer. Collaborated with 12 scientists on projects studying molecular mechanisms of neurological disorders.
oInvestigated the role of gamma-synuclein as a regulator of gene expression and signaling pathways. Established its role as an initiator of the formation of protein aggregates in brain cells.
oExplored the role of caveolins in retinal diseases, including retinal degeneration and glaucoma.
oInvestigated how matrix metalloproteinases MMP-9 and MMP-2 are implicated in glaucoma and other eye diseases.
oPrepared and submitted ~ 15 articles published in high ranking scientific journals.
oPresented 20 oral and poster presentations at the Society for Neuroscience, ARVO and other meetings
oSubmitted several grant proposals, four of which were funded (two in federal institutions and two in private foundations.
oOrganized and oversaw weekly laboratory meetings for research group.
Associate Professor 1998 - 2001 Washington University, St. Louis, MO
Performed structure-function studies of synuclein’s role in health and human diseases. Studied matrix metalloproteinase 9 (MMP-9) in neurodegenerative diseases and cancer.
Wrote and published 5 research papers as a major author. Presented 5 oral and poster presentations.
Oversaw the work of a group of 4 scientists and technicians in the laboratory of retinal biology.
Submitted several grant proposals, 3 of which were funded.
Senior Investigator 1995-1998 University of Utah, UT
Identified a new retinal protein synoretin (gamma-synuclein) and investigated its role in health and diseases.
Published two research papers and made 3 oral/poster presentation at ARVO meetings
1992-1995 Baylor College of Medicine, Houston, TX
Investigated genetic control of lipid metabolism and role of apolipoproteins in cardio-vascular diseases
Established a correlation between polymorphism in apolipoprotein III promoter region and predisposition to hyperlipoproteinemia
Found a role of apolipoprotein E (apo-E) in polymorphisms in coding region and the development of atherosclerosis and hyperlipoproteinemia.
Published five articles in scientific journals.
Ph.D. Biochemistry and Molecular Biology, Moscow University, Russia
M.S. Biochemistry, Moscow University, Russia
B.S. Biochemistry, Moscow University, Moscow, Russia
Society for Neuroscience, 2010 - current
Association for Research of Vision and Ophthalmology (ARVO) 1995 -2010
Invited reviewer for peer review journals 2012- current
Member of Editorial Board in Frontiers in Molecular Neuroscience, Cell Biochemistry and other 10 Scientific Journals, 2012- current
SELECTED PEER-REVIEWED PUBLICATIONS (Out of 70):
Chapters in the books.
1 A. Surguchov. Molecular and cellular biology of synucleins. International Review of Cell and
Molecular Biology, 270, 225-317, 2008.
2 A. Surguchov. Intracellular dynamics of synucleins: Here, there and everywhere. International
Review of Cell and Molecular Biology, 2015, 320:103-169.
3 Surguchov A. in “Protein Aggregation” (Editor: DA Stein). Folding and unfolding of synucleins,
Nova Science Publishers, 2011
4 Surguchov A.” Advances in Brain Research” (Eds: OB. Williams, GI Wilson). “Two Faced
Members of the Family: The Synucleins”, 2012.
5 Surguchov A. Academic Editor. “Synucleins: Biochemistry and role in diseases”, 2018.
6 Surguchov A. Reviewer of the book "Frontiers in Clinical Drug Research - Alzheimer Disorders”.
Bentham Science Publishers. 2018
Articles in peer reviewed journals
Pronin AN, Morris AJ, Surguchov A, Benovic JL. Synucleins are a novel class of substrates for G
protein-coupled receptor kinases. J Biol Chem. 2000, 275, 265**-***** (370 citations).
A. Surguchov, B. McMahon, E. Masliah, I. Surgucheva. Synucleins in ocular tissues. J Neurosci Res,
2001, 65, 68-77
A. Surguchov, RE. Palazzo, and I. Surgucheva. Gamma synucleins: subcellular localization in
neuronal cells and effect on signal transduction. Cell Motility and Cytoskeleton, 2001, 49, 218-228
Surgucheva I., McMahan B, F. Ahmed, Tomarev S, Wax MB, Surguchov A. 2002. Synucleins in
glaucoma. J Neurosci Res, 68: 97-106.
Surgucheva I, Sivak, JM, Fini ME, Palazzo RE and Surguchov A. Effect of -synuclein expression on
matrix metalloproteinases. Arch Biochem Biophys. 2003, 410:167-176.
Maurage CA, Ruchoux MM, De Vos R, Surguchov A, Destee A. Retinal involvement in dementia with
Lewy bodies: A clue to hallucinations? Ann Neurol. 2003, 54 (4):542-7.
Snyder HM, Mensah K, Surgucheva I, Festoff B, Surguchov A, Wolozin B. g-Synuclein prevents
Proteasomal inhibition by α-synuclein but not γ-synuclein. J Biol Chem, 2005. 4; 280:7562-9.
Surgucheva, B. Yue, BC Park, S Tomarev and A. Surguchov. Interaction of myocilin with g-synuclein
and its role in neurodegeneration in glaucoma. Cell Mol Neurobiol, 2005, 25, 6, 1009-33
Surgucheva I, Ninkina N, Buchman VL, Grasing K, A. Surguchov. Protein aggregation in retinal cells
and approaches to cell protection. Cellular Molecular Neurobiology, 2005, 25, 6, 1051-1066.
Surgucheva I, McMahon B., A. Surguchov. Dynamic intracellular localization of g-synuclein: a clue
to its functions. Cell Motility and Cytoskeleton, 2006, 63, 8, 447-458.
Surgucheva I, Surguchov A. 2008. -Synuclein: Cell-Type Specific Promoter Activity and Binding to
Transcription Factors. J Mol Neuroscience, 2008; 35(3):267-71.
A. Surguchov. Molecular and cellular biology of synucleins. International Review of Cell and
Molecular Biology, 2008, 270, 225-317.
I Surgucheva, A Shnyra, J Goldberg, A. Weisman and A Surguchov. -Synuclein as a marker of the
retinal ganglion cells, Molecular Vision, 2008, 14:1540-1548.
I Surgucheva, V Shestopalov and A Surguchov. Effect of -synuclein silencing on apoptotic
pathways in retinal ganglion cells. J Biol Chem, 2008, 284 (52): 36377-85.
A. Surguchev and A. Surguchov. Conformational Diseases: Looking into the eyes. Brain Research
Bulletin, 2010, 81, 12-24
Surgucheva I, Chidambaram K, Willoughby DA, Surguchov A. MicroRNA regulates MMP-9
expression. J Ocular Biology, Diseases and Bioinformatics, 2010; 3: 41-52,
Surgucheva I, McMahon B, Surguchov A. Patterns of synuclein expression throughout lens
development. J Biophys Chem. 2010; 1: 12-18
Surguchov A. in “Protein Aggregation” (Editor: DA. Stein). Folding and unfolding of Synucleins, Nova
Science Publishers, 2011; 7, 179-192
Surgucheva I and Surguchov A. Expression of caveolins in trabecular meshwork cells and its
implication in pathogenesis of glaucoma. Molecular Vision 2011;17: 2878-2888
Surgucheva I, Sharov V; Surguchov, A. -Synuclein: Seeding of α-Synuclein Aggregation and
Transmission Between Cells. Biochemistry, 2012; 51(23):4743-54
Surguchov A. Synucleins: are they two-edged swords? J Neurosci Res, 2013; 91 (2):161-6.
Surguchov A. Parkinson’s disease: Is there a light at the end of a tunnel? (Editorial). Advances in
Parkinson’s Disease, Nov 2013, 2, 3, 116-117.
Surgucheva I, Gunewardena S, Rao HS, Surguchov A. Cell-specific post-transcriptional regulation of
g-synuclein gene by micro-RNAs. PLOS One, Sep 2013, PONE-D-13-25172
Surguchov A. What do synucleins do in the nucleus? (Editorial). Journal of Genetics, Molecular and
Biology, 2014, 1, 1.
Surguchov A. SNCG (synuclein, gamma). Atlas Genet Cytogenet Oncol Haematol. June 2014. URL:
Surgucheva I, Newell KL, Burns J and Surguchov A. New alpha- and gamma-Synuclein
Immunopathological Lesions in Human Brain. Acta Neuropathologica Com, 2014, 2: 132.
Surgucheva I, He S, Sharma R, Rich M, Ninkina NN, Stahel P, Surguchov A. Role of synucleins in
traumatic brain injury. Mol Cell Neurosci. 2014, 63, 114–123.
Surguchev A, Surguchov A. Effect of a-synuclein on membrane permeability and synaptic
transmission: a clue to neurodegeneration? J Neurochemistry, 2015; 132 (6): 619-21
Surguchov A. Intracellular dynamics of synucleins: Here, there and everywhere. International Review
of Cell Molecular Biology, 2015; 320:103-169.
Surguchov A. Atlas of Genetics and Cytogenetics in Oncology and Hematology, 2015, 19, 210-217.
Surguchov A. Parkinson’s disease and cancer: positive and negative associations. OncToday, 2016
Surguchov A. Parkinson’s disease: early diagnosis and association with melanoma. Brain Sci. 2016,
6(2), 17; doi: 10.3390/brainsci6020017.
Surguchov A. Gamma-Synuclein as a cancer biomarker: viewpoint and new approaches.
Oncomedicine, 2016, 1:1-3. doi:10.7150/oncm.16748.
Surguchov A. Type-2 diabetes and Parkinson’s disease: a cross-talk between main players. Journal
of Diabetes Mellitus and Metabolic Syndrome, 2016, 1, 1-7.
Roman A, M Kukharsky, A Surguchov, N Ninkina, V Skvortsova et al. -Synuclein autoantibody in
the serum of patients with CVD and ALS. Annals Biol Sci, 2017, 472, 5.
Surguchov A, Singh V, Surgucheva I, Sharma M, Singh V. New putative epigenetic mechanism of
epilepsy. Frontiers in Neurology, 2017, 8:3. doi: 10.3389/fneur.2017.00003.
Surguchev AA and Surguchov A. Synucleins and gene expression: ramblers in a crowd or cops
regulating traffic? Front. Mol. Neurosci. July 2017, 10, 1-7 224 doi: 10.3389/fnmol.2017.00224
Surguchov A. α-Synuclein Interacts with Lipoproteins in Plasma. Frontiers in Molecular
Neuroscience, 2017, Nov 2, 2017. doi: 10.1007/s12031-017-0967-0.
Emamzadeh FN and Surguchov A. Parkinson’s disease: Biomarkers, Treatment, and Risk Factors .
Frontiers in Neuroscience, Neurodegeneration, 2018 (submitted).
Surguchov A. Academic Editor. “Synucleins: Biochemistry and role in diseases”, 2018.
Surguchov A. Reviewer of the book "Frontiers in Clinical Drug Research - Alzheimer Disorders”.
Bentham Science Publishers. 2018